Evaluation and management approaches for scleroderma lung disease.

Area of Science:

• Rheumatology
• Pulmonology
• Internal Medicine

Background:

• Systemic sclerosis (SSc) frequently leads to interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), major causes of death.
• Symptoms of ILD and PAH in SSc are often subtle or under-reported, delaying diagnosis.
• Early detection and intervention are critical for managing SSc-associated pulmonary complications.

Purpose of the Study:

• To emphasize the importance of early screening for ILD and PAH in systemic sclerosis patients.
• To highlight diagnostic tools and emerging therapeutic strategies for pulmonary involvement in SSc.

Main Methods:

• Review of current literature on SSc, ILD, and PAH.
• Discussion of serological markers, pulmonary function testing, CT scans, and echocardiography for screening.
• Overview of advancements in understanding disease pathogenesis and targeted therapies.

Main Results:

• Serological tests aid in identifying patients at risk for pulmonary issues.
• Pulmonary function tests, CT, and echocardiography are key screening modalities.
• Significant progress in understanding ILD and PAH pathogenesis has spurred new treatments.

Conclusions:

• Early screening and treatment are vital for improving outcomes in SSc patients with pulmonary involvement.
• Advances in understanding pathogenesis have led to novel targeted therapeutics and increased clinical trials for SSc.
• Integrated diagnostic and therapeutic approaches are essential for managing SSc-related lung disease.